a year ago

Beacon Therapeutics Secures $170 Million Series B Funding to Advance Ophthalmic Gene Therapies

  • Beacon Therapeutics, a UK-based ophthalmic gene therapy company, has raised $170 million in Series B funding, bringing the total amount raised to $290 million

  • The round was led by Forbion, with participation from Syncona Limited, Oxford Science Enterprises, the University of Oxford, and initial investors TCGX and Advent Life Sciences

  • The company intends to use the funds to support the clinical development of its lead asset, AGTC-501, for X-Linked Retinitis Pigmentosa (XLRP), and generate Phase 1/2 clinical trial data for its Dry Age-related Macular Degeneration (dAMD) program.

      • ProblemHealthcare

      "Millions of people suffer from vision loss due to various retinal diseases like XLRP and dAMD, resulting in blindness and impacting their quality of life."

      Solution

      "Beacon Therapeutics is developing innovative gene therapies to treat these retinal diseases. Their lead candidate, AGTC-501, targets XLRP and aims to restore vision by delivering a functional copy of the RPGR gene. They are also developing therapies for dAMD, aiming to provide effective treatment options for these debilitating conditions."

      Covered on